Inhibiting ZEB1-mediated immune suppression, either directly or by inhibiting ZEB1-regulated immune modulators like BMPR2, may be a therapeutic approach to promote antitumor immune activity in breast cancer. This evidence concerns the gene BMPR2 and breast carcinoma.